Reports Q4 revenue $4.56M, consensus $7.7M. System revenue was weaker than expected due to delays in hospital construction schedules but does not reflect normalized expectations. “We enter 2024 having made significant progress in realizing our strategic transformation. This is the year in which we expect all the key puzzle pieces to come together, setting us up for breakout growth to follow,” said David Fischel, chairman and CEO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on STXS:
- Stereotaxis Reports 2023 Full Year Financial Results
- Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States
- STXS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Intermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic Technology
- Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
